文献速递心胸血管麻醉

利伐沙班减少模拟体外循环中达比加群所需抗凝剂量

Rivaroxaban Reduces the Dabigatran Dose Required for Anticoagulation During Simulated Cardiopulmonary Bypass.
PubMed 文献 · Anesth Analg · 2022-04-07

本研究在健康供者血中测试达比加群联合利伐沙班在模拟体外循环中的抗凝效果。体外实验显示两药联用具有协同作用;在Chandler环路和模拟CPB回路中,较低浓度达比加群联合利伐沙班可成功维持120分钟无可见血栓,且凝血激活标志物未升高。

要点

  • 达比加群与利伐沙班联用呈协同抗凝,可降低达比加群所需浓度。
  • 模拟CPB中达比加群2500 ng/mL联合利伐沙班200 ng/mL成功运行120分钟。
  • 该联合方案可能为CPB抗凝提供肝素替代选择。

核心结论

  • 达比加群与利伐沙班双联给药在体外产生协同抗凝,并成功预防模拟CPB中凝血。

研究设计与样本

  • 研究使用同意捐献的健康供者血液,依次进行体外凝血分析、Chandler环路和模拟CPB回路实验。

主要发现

  • 达比加群和利伐沙班单药均剂量依赖性延长凝血时间,联用表现为协同作用。
  • Chandler环路中达比加群2400和4800 ng/mL联合利伐沙班150 ng/mL有效预防血栓形成120分钟。
  • 模拟CPB回路中达比加群2500 ng/mL联合利伐沙班200 ng/mL成功运行120分钟并防止纤维蛋白沉积。
  • 模拟CPB期间凝血激活标志物未升高,肝素对照组表现与达比加群联合利伐沙班相似。

关键数值与推荐

  • Chandler环路中达比加群2400和4800 ng/mL联合利伐沙班150 ng/mL可维持120分钟无血栓。
  • 模拟CPB回路中达比加群2500 ng/mL联合利伐沙班200 ng/mL可维持120分钟无血栓。
  • Idarucizumab 250-1000 µg/mL可有效逆转抗凝效果。

临床怎么用

  • 提示达比加群联合利伐沙班可能作为CPB抗凝的潜在替代方案,但尚需临床研究验证。

局限性

  • 研究为体外模拟实验,使用健康供者血液,未在临床CPB患者中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heparin is the standard anticoagulant for cardiopulmonary bypass (CPB); however, there are problems with its use that make the development of suitable alternatives desirable. Currently, no ideal alternative exists. We have previously reported that the direct thrombin inhibitor dabigatran can prevent coagulation in simulated CPB at high concentrations. These high concentrations may cause difficulties in achieving the reversal of dabigatran with idarucizumab, given the markedly different pharmacokinetics of the 2 drugs. Herein, we test the hypothesis that the addition of the anti-Xa drug rivaroxaban would provide suitable anticoagulation at a lower concentration of dabigatran given likely synergy between the 2 classes of drugs. The primary goal of the study was to investigate whether the addition of rivaroxaban reduces the concentration of dabigatran necessary to allow 2 hours of simulated CPB. METHODS: The study was performed in sequential steps. Blood collected from consenting healthy donors was used throughout. First, we added graded concentrations of dabigatran and rivaroxaban alone and in combination and assessed inhibition of anticoagulation using thromboelastometry. Using results from this step, combinations of dabigatran and rivaroxaban were tested in both Chandler loop and simulated CPB circuits. Dabigatran and rivaroxaban were added before recalcification, and the circuits were run for 120 minutes. In both models of CPB, 120 minutes of circulation without visible thrombus was considered successful. In the Chandler loop system, idarucizumab was added to reverse anticoagulant effects. In the CPB circuits, the arterial line filters were examined using scanning electron microscope (SEM) to qualitatively assess for fibrin deposition. RESULTS: In vitro analysis of blood samples treated with dabigatran and rivaroxaban showed that dabigatran and rivaroxaban individually prolonged clotting time (CT) in a dose-dependent manner. However, when combined, the drugs behaved synergistically. In the Chandler loop system, dabigatran 2400 and 4800 ng/mL plus rivaroxaban (150 ng/mL) effectively prevented clot formation and reduced the dynamics of clot propagation for 120 minutes. Idarucizumab (250-1000 µg/mL) effectively reversed anticoagulation. In the CPB circuits, dabigatran (2500 ng/mL) and rivaroxaban (200 ng/mL) were successful in allowing 120 minutes of simulated CPB and prevented fibrin deposition. Biomarkers of coagulation activation did not increase during simulated CPB. Heparin controls performed similarly to dabigatran and rivaroxaban. CONCLUSIONS: The dual administration of oral anticoagulant drugs (dabigatran and Rivaroxaban) with different pharmacologic mechanisms of action produced synergistic inhibition of coagulation in vitro and successfully prevented clotting during simulated CPB.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Nadtochiy SM, Stefanos T, Angona RE, et al. Rivaroxaban Reduces the Dabigatran Dose Required for Anticoagulation During Simulated Cardiopulmonary Bypass. Anesth Analg. 2022. PMID: 35389372. doi:10.1213/ANE.0000000000006019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。